Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein
- PMID: 34903371
- PMCID: PMC8755595
- DOI: 10.1016/j.vaccine.2021.11.087
Antibody responses of healthy adults to the p27 peptide of respiratory syncytial virus fusion protein
Abstract
The respiratory syncytial virus (RSV) fusion (F) protein undergoes two furin-cleavage events to become fusion competent, resulting in the release of a twenty-seven amino acid peptide (p27). Recent studies indicate that the p27 region of the F protein was an immunodominant antigen in young children. In this study, we evaluated the kinetics of the serum antibody response to the p27 peptide following natural RSV reinfection in adults. Nineteen healthy adults under sixty-five years of age were enrolled during the 2018-2019 RSV season in Houston, TX. Blood was collected at three study visits and RSV infection status was defined by changes in neutralizing antibody resulting in three groups: uninfected (n = 12), acutely infected (n = 4), and recently infected (n = 3). Serum IgG and IgA antibodies against RSV/A and RSV/B p27 peptides were measured by enzyme-linked immunosorbent assays, and serum p27-like antibodies were detected by a p27 competitive antibody assay. Anti-p27 antibodies were detected in all subjects at each study visit. The measured IgG and IgA anti-p27 antibody levels followed the same pattern as other RSV site-specific and neutralizing antibody responses described for this cohort previously: the uninfected group had stable responses for the duration of the study period, the acutely infected group had a significant increase following RSV infection, and the recently infected group had a decrease in anti-p27 antibody during the study period. These results indicate that antibodies to the p27 region of the F protein are generated following natural RSV reinfection and suggest that some of the F protein is potentially in a partially cleaved state on the surface of virions, expanding on the previous assumption that all of p27 is post-translationally released and not present on mature F. Additionally, antibody responses were significantly lower (1.4-1.5-fold) toward RSV/B than to RSV/A p27 at each study visit, despite being an RSV/B dominant outbreak. Understanding the mechanism for the differences in the magnitude of the RSV/A and RSV/B p27 antibody response may enhance our understanding of the intracellular processing of the F protein.
Keywords: Furin cleavage site; Fusion protein; P27 peptide; Pneumovirus; Respiratory syncytial virus.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Potential conflicts of interest All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Figures
Similar articles
-
The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent.J Virol. 2023 May 31;97(5):e0025423. doi: 10.1128/jvi.00254-23. Epub 2023 May 3. J Virol. 2023. PMID: 37133390 Free PMC article.
-
A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas.Vaccine. 2021 Feb 22;39(8):1248-1256. doi: 10.1016/j.vaccine.2021.01.045. Epub 2021 Jan 26. Vaccine. 2021. PMID: 33509697 Free PMC article.
-
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12. Vaccine. 2019. PMID: 31416644
-
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827. doi: 10.1007/s10096-018-3289-4. Epub 2018 Jun 6. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29876771 Review.
-
Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine.Expert Rev Vaccines. 2021 Apr;20(4):351-364. doi: 10.1080/14760584.2021.1903877. Epub 2021 May 2. Expert Rev Vaccines. 2021. PMID: 33733995 Review.
Cited by
-
Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-like Illness in Sicily (Italy) from 2017 to 2023.Viruses. 2024 May 26;16(6):851. doi: 10.3390/v16060851. Viruses. 2024. PMID: 38932144 Free PMC article.
-
The RSV F p27 peptide: current knowledge, important questions.Front Microbiol. 2023 Jun 21;14:1219846. doi: 10.3389/fmicb.2023.1219846. eCollection 2023. Front Microbiol. 2023. PMID: 37415824 Free PMC article. Review.
-
The Efficiency of p27 Cleavage during In Vitro Respiratory Syncytial Virus (RSV) Infection Is Cell Line and RSV Subtype Dependent.J Virol. 2023 May 31;97(5):e0025423. doi: 10.1128/jvi.00254-23. Epub 2023 May 3. J Virol. 2023. PMID: 37133390 Free PMC article.
References
-
- Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017. Sep 2;390(10098):946–958. doi: 10.1016/S0140-6736(17)30938-8. Epub 2017 Jul 7. - DOI - PMC - PubMed
-
- Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010. May 1;375(9725):1545–55. doi: 10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous